2Anne-marie M, Ying L, Jacque-Philippe C, et al. Ex vivo expansion of megakaryocytic cells. Int J Hematol,2000,71 : 203-210.
3Long MW. Population heterogeneity among cells of the megakaryocyte lineage.Stem Cells,1993, 11:33-40.
4Jackson H, Williams N, Bertoncello I, et al. Classes of primitive murine megakaryocytic progenitor cells. Exp Hematol,1994 , 22: 954-958.
5Bruno E, Murray LJ, DiGusto R, et al. Detection of a primitive megakaryocyte progenitor cell in human fetal bone marrow. Exp Hematol,1996,24: 552-558.
6Ramshaw HS, Haylock D, Swart B. Monoclonal antibody BB9 raised against bone marrow stromal cells identifies a cell-surface glycoprotein expressed by primitive human hemopoietic progenitors. Exp Hematol, 2001,29:981-992.
7Briddell RA, Brandt JE, Straneva JE, et al. Characterization of the human burst-forming unit-megakaryocyte. Blood,1989,4: 145-151.
8Briddell RA, Hoffman R. Cytokine regulation of the human burst-forming unit-megakaryocyte. Blood,1990,76: 516-522.
9Han ZC. Identification of a murine high-proliferative-potential colony-forming cell (HPP-CFC) capable of producing a number of megakaryocytes and replating for secondary HPP-CFCs in culture. J Lab Clin Med,1994,123: 610-616.
10Lowry PA, Dean DA, Whitefield P, et al. The high-proliferative-potential megakaryocyte mixed (HPP-Meg-Mix) cell: a trilineage murine hematopoietic progenitor with multiple growth factor responsiveness. Exp Hematol,1995, 23:1135-1140.
二级参考文献23
1Tao H, Gaudry L, Rice A, et al. Cord blood is better than bone marrow for generating megakaryocytic progenitor cells. Exp Hematol,1999;27:293-301
2Schatmer M, Lefebvre P, Mingolelli SS, et al. Thrombopoietinstimulated ex vivo expansion of human bone marrow megakaryocytes. Stem Cells,1996;14:207-214
3van den Oudenrijn S, von dcm Borne AE, de Haas M. Influence of medium components on ex vivo megakaryocyte expansion. J Hematother Stem Cell Res,2001;10:193-200
4Lefebvre P, Winter JN, Kahn LE, et al. Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium. J Hematother,1999;8:199-208
5Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood,2002;
6Watts MJ, Somervaille TC, Ings SJ, et al. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices. BrJ Haematol,2002;118:117-123
7Lazzari L, Henschler R, Leechi L, et al. Interleukin-6 and interleukin-11 act synergistically with thrombopoietin and stem cell factor to modulate ex vivo expansion of human CD41+ and CD61+megakaryocytic cells. Haematologica,2000;85:25-30
8van den Oudenrijn S, von dem Bome AE, de Haas M. Differences in megakaryocyte expansion potential between CD34 + stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp Hematol,2000;28:1054-1061
9Mwarmtemi HH, Higuchi T, Sawai N, et al. Quantitative and qualitative differences in thrombopoietin-dependent hematopoietic progenitor development between cord blood and bone marrow. Transplantation,2000;69:1645-1654
10Bruno S, Gunetti M, Gammaitoni L, et al. In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution.Haematologica,2003;88:379-387
